December 10-12, Gene Therapy for Neurological Disorder, Boston
On 10-12 December the scientific conference Gene Therapy for Neurological Disorders (https://gtxn-summit.com/) will be held in Boston. Naturally, CombiGene will be on hand for this important event and has been invited to present a poster on the company’s CG01 epilepsy project – a definite sign that CombiGene’s science and efforts are starting to attract international attention.
CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations. The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 email@example.com.